Glaxo: Tesaro Asset Dostarlimab Showing Positive Results
19 Março 2019 - 3:43PM
Dow Jones News
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) said Tuesday that a clinical trial
of its cancer drug dostarlimab yielded positive preliminary
results.
The ongoing study, called Garnet, is examining the effects of
dostarlimab on women with advanced or recurrent endometrial cancer
who had their disease progress after chemotherapy. Dostarlimab is
an asset that Glaxo acquired when it bought oncology specialist
Tesaro Inc. in December 2018.
Data shows that dostarlimab administration of is having an
effect on the disease, Glaxo said. The British pharmaceutical
company said that disease control rate--a measure of efficacy of
treatment--totaled 53% for patients administered the drug.
The study revealed that so far, 88 out of 125 patients had at
least one adverse even in the course of treatment, but these were
for the most part low-grade. Glaxo said that 13.6% of patients
experienced grade 3 or higher events, and no deaths occurred due to
treatment.
The FTSE 100-listed drugmaker said it plans to submit a license
application for the drug as a treatment for endometrial cancer at
the end of 2019.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
March 19, 2019 14:28 ET (18:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Gsk (LSE:GSK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
